What is claimed is:

1. A pharmaceutical composition which comprises orlistat and a pharmaceutically acceptable bile acid sequestrant selected from the group consisting of DEAE-cellulose, guanidinoethylcellulose, and DEAE-Sephadex.

2. The composition according to claim 1, wherein the composition comprises (a) from about 5 to about 1000 mg of orlistat and (b) from about 0.1 to about 20 g of the bile acid sequestrant.

3. The composition according to claim 2, which comprises:

(a) from about 5 to about 1000 mg of orlistat;

(b) from about 0.1 to about 20 g bile acid sequestrant selected from the group consisting of DEAE-cellulose, guanidinoethylcellulose, and DEAE-Sephadex;

(c) from about 0.1 to about 10 g of a filler;

(d) from about 0.05 to about 3.0 g of a surfactant;

(e) from about 0.05 to about 2.0 g of a disintegrant;

(f) from about 0.02 to about 2.0 g of a binder;

(g) from about 0.001 to about 1.0 g of a lubricant;

(h) from about 0.1 to about 5.0 g of a flowability enhancer;

(i) from about 0.01 to about 4.0 g of a sweetener; and

(j) and about 0.001 to about 0.5 g of a colorant.

4. The compositions according to claim 3, wherein the orlistat is present in an amount of from about 10 to about 500 mg.

5. The composition according to claim 4, wherein the orlistat is present in an amount of about 120 mg.

6. The composition according to claim 4, wherein the orlistat is present in an amount of from about 20 to about 100 mg.

7. The composition according to claim 6, wherein the orlistat is present in an amount of about 60 mg.

8. The composition according to claim 4, wherein the bile acid sequestrant is present in an amount of from about 0.5 to about 10 g.

9. The composition according to claim 8, wherein the bile acid sequestrant is present in an amount of from about 1 to about 5 g.

10. A pharmaceutical composition which comprises orlistat and a pharmaceutically acceptable acid sequestrant selected from the group consisting of cholestyramine, colestipol, colestimide, colesevelam, sevelamer, DEAE-cellulose, β- cyclodextrin, and γ-cyclodextrin.

11. The composition according to claim 10, wherein pharmaceutically acceptable bile acid sequestrant is selected from the group consisting of β-cyclodextrin and γ-cyclodextrin.

12. The composition according to claim 10, wherein the bile acid sequestrant is selected from the group consisting of cholestyramine, colestipol, sevelamer, DEAE-cellulose, β-cyclodextrin, and γ-cyclodextrin.

13. The composition according to claim 12, wherein the bile acid sequestrant is selected from the group consisting of cholestyramine, colestipol, and sevelamer.

14. The composition according to claim 13, wherein the bile acid sequestrant is cholestyramine.

15. The composition according to claim 13, wherein the bile acid sequestrant is colestipol.

16. The composition according to claim 13, wherein the bile acid sequestrant is sevelamer.

17. The composition according to claim 10, wherein the composition comprises (a) from about 5 to about 1000 mg of orlistat and (b) from about 0.1 to about 20 g of the bile acid sequestrant.

18. The composition according to claim 17, which comprises:

(a) from about 5 to about 1000 mg of orlistat;

(b) from about 0.1 to about 20 g bile acid sequestrant selected from the group consisting of cholestyramine, colestipol, colestimide, colesevelam, sevelamer, DEAE-cellulose, β- cyclodextrin, and γ-cyclodextrin;

(c) from about 0.1 to about 10 g of a filler;

(d) from about 0.05 to about 3.0 g of a surfactant;

(e) from about 0.05 to about 2.0 g of a disintegrant;

(f) from about 0.02 to about 2.0 g of a binder;

(g) from about 0.001 to about 1.0 g of a lubricant;

(h) from about 0.1 to about 5.0 g of a flowability enhancer;

(i) from about 0.01 to about 4.0 g of a sweetener; and

(j) and about 0.001 to about 0.5 g of a colorant.

19. The composition according to claim 14, wherein the composition comprises (a) from about 5 to about 1000 mg of orlistat and (b) from about 0.1 to about 20 g of the bile acid sequestrant.

20. The composition according to claim 19, which comprises:

(a) from about 5 to about 1000 mg of orlistat;

(b) from about 0.1 to about 20 g bile acid sequestrant selected from the group consisting of cholestyramine, colestipol, colestimide, colesevelam, sevelamer, DEAE-cellulose, β- cyclodextrin, and γ-cyclodextrin;

(c) from about 0.1 to about 10 g of a filler;

(d) from about 0.05 to about 3.0 g of a surfactant;

(e) from about 0.05 to about 2.0 g of a disintegrant;

(f) from about 0.02 to about 2.0 g of a binder;

(g) from about 0.001 to about 1.0 g of a lubricant;

(h) from about 0.1 to about 5.0 g of a flowability enhancer;

(i) from about 0.01 to about 4.0 g of a sweetener; and

(j) and about 0.001 to about 0.5 g of a colorant.

21. The compositions according to claim 17, wherein the orlistat is present in an amount of from about 10 to about 500 mg.

22. The composition according to claim 21, wherein the orlistat is present in an amount of about 120 mg.

23. The composition according to claim 17, wherein the orlistat is present in an amount of from about 20 to about 100 mg.

24. The composition according to claim 23, wherein the orlistat is present in an amount of about 60 mg.

25. The composition according to claim 17, wherein the bile acid sequestrant is present in an amount of from about 0.5 to about 10 g.

26. The composition according to claim 25, wherein the bile acid sequestrant is present in an amount of from about 1 to about 5 g.

27. The compositions according to claim 19, wherein the orlistat is present in an amount of from about 10 to about 500 mg.

284. The composition according to claim 27, wherein the orlistat is present in an amount of about 120 mg.

29. The composition according to claim 27, wherein the orlistat is present in an amount of from about 20 to about 100 mg.

30. The composition according to claim 29, wherein the orlistat is present in an amount of about 60 mg.

31. The composition according to claim 19, wherein the bile acid sequestrant is present in an amount of from about 0.5 to about 10 g.

32. The composition according to claim 31, wherein the bile acid sequestrant is present in an amount of from about 1 to about 5 g.

33. A kit for use in the treatment of obesity, which comprises (a) a first component which is orlistat and (b) a second component which is a bile acid sequestrant selected from the group consisting of cholestyramine, colestipol, colestimide, colesevelam, sevelamer, DEAE-cellulose, β- cyclodextrin, γ-cyclodextrin, guanidinoethylcellulose, and DEAE-Sephadex, present in oral unit dosage form.

34. A method of treating obesity in an obese patient to achieve a reduction in body weight, which comprises administering to a patient in need of such treatment (a) a therapeutically effective amount of orlistat and (b) a pharmaceutically acceptable bile acid sequestrant selected from the group consisting of cholestyramine, colestipol, colestimide, colesevelam, sevelamer, DEAE-cellulose, β- cyclodextrin, γ-cyclodextrin, guanidinoethylcellulose, and DEAE-Sephadex in an amount effective to reduce gastrointestinal side effects associated with the lipase inhibitor.

35. The method according to claim 34, wherein the orlistat and bile acid sequestrant are administered simultaneously.

36. The method according to claim 34, wherein the orlistat and bile acid sequestrant are administered separately.

37. The method according to claim 34, wherein the orlistat and bile acid sequestrant are administered sequentially.